Jazz Pharmaceuticals' Phase I ONC206 trial in CNS neoplasms updated, remains active not recruiting
Registry record for the first-in-human ONC206 study was updated as the trial continues dose escalation toward an estimated 2027 primary completion.
A single update this week concerns Jazz Pharmaceuticals' early-stage trial of oral ONC206 in central nervous system tumors.
- "A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms" (NCT04541082) remains listed as active, not recruiting, with Jazz Pharmaceuticals as lead sponsor and the National Institutes of Health as collaborator. It is anticipated that approximately 46 patients will be enrolled in order to determine the MTD of ONC206.1 The record's last update was posted November 9, 2026, with primary completion estimated for March 31, 2027.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.